Similar articles

• L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.

  Goodwin FK, Murphy DL, Brodie HK, Bunney WE Jr. Goodwin FK, et al. Biol Psychiatry. 1970 Oct;2(4):341-66. Biol Psychiatry. 1970. PMID: 4920729 Review. No abstract available.
• Depressive symptomatology and drug response.

  Bech P. Bech P. Commun Psychopharmacol. 1978;2(5):409-18. Commun Psychopharmacol. 1978. PMID: 216525 No abstract available.
• [Clorgyline and Lilly 51641 suppression of the withdrawal syndrome induced by naloxone in morphine-dependent mice].

  Garzón J, Fuentes JA, del Río J. Garzón J, et al. Arch Farmacol Toxicol. 1978 Apr;4(1):77-9. Arch Farmacol Toxicol. 1978. PMID: 567958 Spanish. No abstract available.
• The effect of augmentation with moclobemide on symptoms of schizophrenia.

  Silver H, Aharon N, Hausfater N, Jahjah N. Silver H, et al. Int Clin Psychopharmacol. 1999 May;14(3):193-5. Int Clin Psychopharmacol. 1999. PMID: 10435775 Clinical Trial.
• [Sleep disorders in schizophrenia].

  Staedt J, Hauser M, Gudlowski Y, Stoppe G. Staedt J, et al. Fortschr Neurol Psychiatr. 2010 Feb;78(2):70-80. doi: 10.1055/s-0028-1109967. Epub 2010 Jan 11. Fortschr Neurol Psychiatr. 2010. PMID: 20066610 Review. German.